Curated News
By: NewsRamp Editorial Staff
October 08, 2026
Lantern Pharma to Present at ThinkEquity Conference on Oct. 15, 2026
TLDR
- Lantern Pharma will present at the ThinkEquity Conference on Oct. 15, 2026, offering investors direct access to its AI-driven oncology pipeline.
- Lantern Pharma uses its RADR AI platform to integrate genomic data and identify patients most likely to benefit from its cancer therapies.
- Lantern Pharma's AI platform aims to accelerate precision oncology, potentially bringing better cancer treatments to patients faster.
- Lantern Pharma's RADR AI platform analyzes large-scale biological data to guide biomarker-driven clinical development for targeted cancer therapies.
Impact - Why it Matters
This news matters because it provides investors with a direct opportunity to hear from Lantern Pharma's management about the company's progress and vision. As an AI-driven oncology company, Lantern Pharma is at the intersection of two rapidly growing fields: artificial intelligence and precision medicine. The RADR platform's potential to streamline drug development and improve patient outcomes could significantly disrupt the traditional oncology landscape. Investors attending the presentation or tuning into the webcast will gain insights into Lantern's pipeline, including LP-184, LP-300, and LP-284, as well as its subsidiaries, Starlight Therapeutics and Open-Medicine AI. Such events can influence market perception and investment decisions, especially for a clinical-stage company where milestones and data readouts are critical. Moreover, the involvement of InvestorWire and IBN underscores the importance of effective communication in reaching a broad investor base. As AI continues to revolutionize healthcare, Lantern Pharma's advancements could lead to more personalized and effective cancer treatments, making this a noteworthy event for both the medical and investment communities.
Summary
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of AI-driven oncology drug development, has announced that its management team will present at the upcoming ThinkEquity Conference. The event is scheduled for October 15, 2026, at 3:30 p.m. ET and will take place at the Mandarin Oriental in New York City. Investors and interested parties can access the presentation via a live webcast, and Lantern Pharma management will also be available for one-on-one investor meetings throughout the conference, providing a valuable opportunity for direct engagement.
Lantern Pharma is leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For the full press release, visit https://ibn.fm/hmTGq.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions, editorial syndication to over 5,000 outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. This collaboration ensures that Lantern Pharma’s news reaches a wide audience of investors, influencers, and journalists. For more information, visit https://www.InvestorWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma to Present at ThinkEquity Conference on Oct. 15, 2026
